Diabetic Peripheral Neuropathy (DPN)

Also known as: Diabetic Peripheral Neuropathy / Diabetic neuropathy / Diabetic Neuropathies

DrugDrug NameDrug Description
DB00476DuloxetineDuloxetine (brand names Cymbalta, Yentreve, and in parts of Europe, Xeristar or Ariclaim) is a drug which primarily targets major depressive disorder (MDD), generalized anxiety disorder (GAD), pain related to diabetic peripheral neuropathy and in some countries stress urinary incontinence (SUI). It is manufactured and marketed by Eli Lilly and Company. Duloxetine has not yet been FDA approved for stress urinary incontinence or for fibromyalgia. Duloxetine is a selective SNRI (selective serotonin-norepinephrine reuptake inhibitor). Duloxetine is a systemic drug therapy which affects the body as a whole. Known also under the code name LY248686, it is a potent dual reuptake inhibitor of serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE), possessing comparable affinities in binding to NE- and 5-HT transporter sites. It is a less potent inhibitor of dopamine reuptake.
DrugDrug NamePhaseStatusCount
DB00742Mannitol1 / 2Recruiting1
DB00825Menthol1 / 2Recruiting1
DB04889Bicifadine2Unknown Status1
DB05492Epicept NP-12Completed1
DB00996Gabapentin2Completed1
DB00230Pregabalin2Completed2
DB12335Tanezumab2Terminated1
DB06774Capsaicin3Completed1
DB00230Pregabalin3Completed2
DB06204Tapentadol3Completed1
DB00230Pregabalin4Completed1
DB01632Alpha-Phosphoribosylpyrophosphoric AcidNot AvailableRecruiting1
DB01276ExenatideNot AvailableCompleted1
DB00047Insulin GlargineNot AvailableCompleted1